Pharmaceutical

Oragenics acquires neurological assets from Odyssey Health

Oragenics has concluded the announced acquisition of assets focusing on neurological drug therapies and technologies from Odyssey Health.

Jan 3, 2024 - 18:00
Oragenics acquires neurological assets from Odyssey Health
Oragenics has concluded the announced acquisition of assets focusing on neurological drug therapies and technologies from Odyssey Health.
Read the original article

Tags:

Previous Article

UK MHRA introduces new procedure for medicine approvals

Next Article

EMA validates BMS’s repotrectinib application to treat cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

IMIDomics to license TNAX’s drug candidate for IMIDs

IMIDomics to license TNAX’s drug candidate for IMIDs

Sep 7, 2023

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

Mar 16, 2024

STAT+: Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion

STAT+: Merck to acquire Prometheus Biosciences, maker o...

Apr 17, 2023